Relay Therapeutics Inc Aktie News

Donald Bergstrom sold 21,581 shares over Jan. 27 and Jan. 28, 2026, generating a total value of approximately $166,700 at a weighted average price around $7.72 per share. This transaction reduced his direct holdings by 4.89%, leaving him with 420,047 directly held shares post-sale.

CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease, today announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, Februa...

Designation supported by robust clinical  data from ReDiscover trial with 600mg BID fasted and 400mg BID fed doses of zovegalisib in combination with fulvestrant Initial Phase 1/2 data of zovegalisib + fulvestrant at the 400mg BID fed (Phase 3 dose) in CDK4/6-experienced patients to be presented at ESMO Targeted Anticancer Therapies Congress on March 16 CAMBRIDGE, Mass., Feb. 03, 2026 (GLOBE NE...

Relay Therapeutics is upgraded to Outperform with a $14 price target, driven by optimism for zovegalisib in PIK3CA-mutant HR+/HER2- metastatic breast cancer. Zovegalisib's mutant-selective PI3Kα inhibition offers a differentiated safety and efficacy profile versus broader PI3K inhibitors, targeting a large, underserved patient population. RLAY's $596M cash position funds operations into 2029, s...

Efficacy data remain consistent with previous disclosures, showing 10.3-month median PFS in all patients and 11.4-month median PFS in 2L patients Subset analyses show broad activity in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer, regardless of prior fulvestrant or other SERD exposure, or ESR1 mutation status Phase 3 ReDiscover-2 trial in CDK4/6-experienced breast cancer ongo...

Chief Corporate Development Officer Peter Rahmer sold more than 40,000 shares of Relay Therapeutics in October. The sale, worth about $300,000, was partially due to company policy regarding vested restricted stock units.

New York City-based Commodore Capital increased its RLAY position by 3,650,000 shares in the third quarter. The transaction value represented 0.7% of Commodore's 13F AUM for the period.

Relay Therapeutics, Inc. ( RLAY ) Jefferies London Healthcare Conference 2025 November 19, 2025 6:30 AM EST Company Participants Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Conference Call Participants Zaki Molvi - Jefferies LLC, Research Division Presentation Zaki Molvi Jefferies LLC, Research Division All right. Good morning, everyone.